Efficacy and Safety of Q-122 for Treating Vasomotor Symptoms in Women With Breast Cancer Taking Tamoxifen or Aromatase Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial
Lancet 2022 Nov 12;400(10364)1704-1711, A Vrselja, A Latifi, RJ Baber, BGA Stuckey, MG Walker, V Stearns, M Hickey, SR DavisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.